Sign In
Buy AUTL
$1.62
-0.130 (-7.43%)
At Close: Jun 03, 2026
Strength Seen in Autolus Therapeutics PLC Sponsored ADR (AUTL): Can Its 6.3% Jump Turn into More Strength?
03:31am, Monday, 12'th Feb 2024
Autolus Therapeutics PLC Sponsored ADR (AUTL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't sugges
Autolus Announces Pricing of Underwritten Offering
07:00am, Thursday, 08'th Feb 2024
LONDON, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced th
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
05:45am, Thursday, 08'th Feb 2024
Strategic alliance leverages manufacturing and commercial infrastructure as well as technology with the aim to advance both companies' autologous CAR-T programs towards market, pending market authoriz
Autolus Upgrades Leadership And Faces CAR-T Approval
09:52am, Tuesday, 06'th Feb 2024
Obe-cel continues to demonstrate comparative efficacy with fewer side effects to approved therapies. Thus, the company will likely gain its first market authorization in November. Autolus made several
The Jobs Report Blows Away Forecasts
09:26pm, Friday, 02'nd Feb 2024
January's payrolls report shows 353,000 jobs
Autolus Therapeutics announces publication in ACS Chemical Biology
07:00am, Tuesday, 23'rd Jan 2024
LONDON, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced a
PDUFA Goal date is November 16, 2024 Company on track to submit a marketing authorization application to the European Medicines Agency (EMA) in the first half of 2024 LONDON, Jan. 22, 2024 (GLOBE NEWS
Autolus Therapeutics Announces Changes to its Board of Directors
07:00am, Friday, 22'nd Dec 2023
- Appointment of Elisabeth (“Lis”) Leiderman, M.D. - Resignation of Kapil Dhingra, M.D.
Autolus Therapeutics: Pivotal Trial Using Familiar Approach, Possible Approval Coming Fast
04:12am, Monday, 18'th Dec 2023
Autolus Therapeutics is developing cell-based immunotherapy for cancer, focusing on CD19 in ALL. Their flagship product, obe-cel, has shown promising results in treating relapsed/refractory B-cell ALL
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
08:30pm, Saturday, 09'th Dec 2023
Pooled analysis of the FELIX Phase Ib/II study demonstrated prolonged event free survival and low overall immunotoxicity across all cohorts in r/r B-ALL, and particularly in patients with low leukemic
BLA submission includes results from pivotal Phase 2 FELIX study evaluating obe-cel in relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL) Company on track to submit a marketing
Autolus Therapeutics announces participation in upcoming conferences
07:00am, Monday, 06'th Nov 2023
LONDON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces i
Autolus Therapeutics plc (AUTL) Q3 2023 Earnings Call Transcript
10:05pm, Friday, 03'rd Nov 2023
Autolus Therapeutics plc (NASDAQ:AUTL ) Q3 2023 Earnings Conference Call November 2, 2023 9:00 AM ET Company Participants Julia Wilson – Investor Relations Christian Itin – Chief Executive Officer
Correction - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023
08:07am, Wednesday, 11'th Oct 2023
LONDON, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced t
Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023
07:00am, Wednesday, 11'th Oct 2023
LONDON, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced t
